Currently most attempts at cancer immunotherapy involve the generation of CD8+ cytotoxic T lymphocytes (CTLs) against tumor-associated antigens. Many tumors, however, have been immunoselected to evade recognition by CTLs and thus alternative approaches to cancer immunotherapy are urgently needed. Here we demonstrate that CD4+ T cells that recognize a secreted tumor-specific antigen and exhibit a cytokine secretion profile characteristic of Th2 cells, are capable of clearing established lung and visceral metastases of a CTL-resistant melanoma. Clearance of lung metastases by the Th2 cells was found to be totally dependent on the eosinophil chemokine, eotaxin, and partially dependent on the transcription activator signal transducer and activator of transcription 6 (STAT6), with degranulating eosinophils within the tumors inducing tumor regression. In contrast, tumor-specific CD4+ Th1 cells, that recruited macrophages into the tumors, had no effect on tumor growth. This work provides the basis for a new approach to adoptive T cell immunotherapy of cancer.
Skip Nav Destination
Article navigation
3 February 2003
Brief Definitive Report|
January 27 2003
Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells : An Eotaxin and STAT6-dependent Process
Joerg Mattes,
Joerg Mattes
1Division of Molecular Bioscience, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
Search for other works by this author on:
Mark Hulett,
Mark Hulett
2Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
Search for other works by this author on:
Wei Xie,
Wei Xie
2Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
Search for other works by this author on:
Simon Hogan,
Simon Hogan
1Division of Molecular Bioscience, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
Search for other works by this author on:
Marc E. Rothenberg,
Marc E. Rothenberg
3Division of Allergy and Immunology, Department of Pediatrics, Children's Hospital Medical Center, Cincinnati, OH 45229
Search for other works by this author on:
Paul Foster,
Paul Foster
1Division of Molecular Bioscience, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
Search for other works by this author on:
Christopher Parish
Christopher Parish
2Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
Search for other works by this author on:
Joerg Mattes
1Division of Molecular Bioscience, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
Mark Hulett
2Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
Wei Xie
2Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
Simon Hogan
1Division of Molecular Bioscience, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
Marc E. Rothenberg
3Division of Allergy and Immunology, Department of Pediatrics, Children's Hospital Medical Center, Cincinnati, OH 45229
Paul Foster
1Division of Molecular Bioscience, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
Christopher Parish
2Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia
Address correspondence to Christopher Parish or Paul Foster, Division of Immunology and Genetics, John Curtin School of Medical Research, Australian National University, Canberra ACT 2601, Australia. Phone: 61-2-61252604; Fax: 61-2-61252595; E-mail: [email protected] or [email protected]
Received:
September 24 2002
Revision Received:
December 10 2002
Accepted:
December 12 2002
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2003
J Exp Med (2003) 197 (3): 387–393.
Article history
Received:
September 24 2002
Revision Received:
December 10 2002
Accepted:
December 12 2002
Citation
Joerg Mattes, Mark Hulett, Wei Xie, Simon Hogan, Marc E. Rothenberg, Paul Foster, Christopher Parish; Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells : An Eotaxin and STAT6-dependent Process . J Exp Med 3 February 2003; 197 (3): 387–393. doi: https://doi.org/10.1084/jem.20021683
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement